New drug combo targets persistent 'Mono' virus disease

NCT ID NCT07369739

Recruiting now Disease control Sponsor: Beijing Friendship Hospital Source: ClinicalTrials.gov ↗

Summary

This study is testing whether combining two drugs, golidocitinib and selinexor, can help control chronic active Epstein-Barr virus disease (CAEBVD). Researchers will enroll 28 adults with CAEBVD to see if this combination reduces disease activity and lowers virus levels in the blood. The goal is to find a better treatment option for this rare condition where the virus stays active and causes ongoing health problems.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Friendship Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CAEBV EBV LYMPHOHISTIOCYTOSIS